Advertisement

Apoptotic effect of fluoxetine through the endoplasmic reticulum stress pathway in the human gastric cancer cell line AGS

  • Phyu Phyu Khin
  • Wah Wah Po
  • Wynn Thein
  • Uy Dong SohnEmail author
Original Article

Abstract

Gastric cancer is the fourth most common cancer in the world. Fluoxetine (FLX), a selective serotonin reuptake inhibitor, can inhibit the growth of cancer cells by inducing apoptotic cell death through various signaling pathways. This study was aimed to determine the mechanism of apoptotic cell death induced by FLX in AGS cells. MTT assay for cell viability test and colony forming assay was performed for detection of cell proliferation. Western blot analysis was conducted for protein expression. Increased fluorescence intensity and chromatin condensation were observed using DAPI staining. Production of reactive oxygen species (ROS) was measured by DCFDA assay. AGS cell proliferation was remarkedly inhibited by FLX in a dose-dependent manner starting at a concentration of 20 μM. The expression of death receptors was increased, which resulted in elevated expression of activated caspases and cleaved PARP, leading to FLX-induced apoptosis. Moreover, FLX significantly increased production of ROS, and N-acetyl cysteine, which scavenges ROS, attenuated the cytotoxic effects of FLX. In addition, treatment with FLX increased the expression of the endoplasmic reticulum (ER) stress marker, CHOP. P53 protein expression in AGS cells also decreased significantly with FLX treatment. Inhibition of ER stress significantly decreased the expressions of death receptor 5 (DR5), cleaved caspase 3, and cleaved PARP, but not to control levels. FLX-induced apoptosis in AGS involved upregulation of death receptors, ROS generation, and activation of ER stress.

Keywords

Gastric adenocarcinoma Fluoxetine Apoptosis ROS Endoplasmic reticulum stress 

Notes

Acknowledgments

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea and funded by the Ministry of Education, Science and Technology [Grant 2016R1D1A1A09918019].

Author contribution

PPK and UDS conceived and designed research. PPK and WWP conducted experiments. PPK and WT analyzed data. PPK wrote the manuscript. All authors read and approved the manuscript.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have is no conflict of interest.

References

  1. Bagci EZ, Vodovotz Y, Billiar TR, Ermentrout GB, Bahar I (2006) Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J 90:1546–1559PubMedCrossRefGoogle Scholar
  2. Barbey JT, Roose SP (1998a) SSRI safety in overdose. J Clin Psychiatry 59:42–48PubMedGoogle Scholar
  3. Barbey JT, Roose SP (1998b) SSRI safety in overdose. J Clin Psychiatry 59(Suppl 15):42–48PubMedGoogle Scholar
  4. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M (1999) Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274:22932–22940PubMedCrossRefGoogle Scholar
  5. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL, Hogg GR, Warrington RC, Fang W, LaBella FS (1992) Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52:3796–3800PubMedGoogle Scholar
  6. Charles E, Hammadi M, Kischel P, Delcroix V, Demaurex N, Castelbou C, Vacher AM, Devin A, Ducret T, Nunes P, Vacher P (2017) The antidepressant fluoxetine induces necrosis by energy depletion and mitochondrial calcium overload. Oncotarget 8:3181–3196PubMedCrossRefGoogle Scholar
  7. Cheer SM, Goa KL (2001) Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 61:81–110PubMedCrossRefGoogle Scholar
  8. Choi JH, Jeong YJ, Yu AR, Yoon KS, Choe W, Ha J, Kim SS, Yeo EJ, Kang I (2017) Fluoxetine induces apoptosis through endoplasmic reticulum stress via mitogen-activated protein kinase activation and histone hyperacetylation in SK-N-BE(2)-M17 human neuroblastoma cells. Apoptosis 22:1079–1097PubMedCrossRefGoogle Scholar
  9. Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 162:835–838PubMedCrossRefGoogle Scholar
  10. de Oliveira MR (2016) Fluoxetine and the mitochondria: a review of the toxicological aspects. Toxicol Lett 258:185–191PubMedCrossRefGoogle Scholar
  11. Hsieh YH, Chiu WC, Lin CF, Chan HL, Liang HY, Lee Y, McIntyre RS, Chen VC (2015) Antidepressants and gastric cancer: a nationwide population-based nested case-control study. PLoS One 10:e0143668PubMedPubMedCentralCrossRefGoogle Scholar
  12. Huo Y-L, Qiao J-M, Gao S (2018) Association between antidepressant medication use and epithelial ovarian cancer risk: a systematic review and meta-analysis of observational studies. 84:649–658Google Scholar
  13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRefGoogle Scholar
  14. Kannen V, Hintzsche H, Zanette DL, Silva WA Jr, Garcia SB, Waaga-Gasser AM, Stopper H (2012) Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model. PLoS One 7:e50043PubMedPubMedCentralCrossRefGoogle Scholar
  15. Khodapasand E, Jafarzadeh N, Farrokhi F, Kamalidehghan B, Houshmand M (2015) Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer? Iran Biomed J 19:69–75PubMedPubMedCentralGoogle Scholar
  16. Kiridly-Calderbank J, Sturgeon SR, Kroenke CH, Reeves KW (2018) Antidepressant use and risk of colorectal cancer in the women's health initiative. cebp.1035.2017Google Scholar
  17. Koh SJ, Kim JM, Kim IK, Kim N, Jung HC, Song IS, Kim JS (2011) Fluoxetine inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am J Physiol Gastrointest Liver Physiol 301:G9–G19PubMedCrossRefGoogle Scholar
  18. Lee CS, Kim YJ, Jang ER, Kim W, Myung SC (2010) Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin Pharmacol Toxicol 106:446–453PubMedCrossRefGoogle Scholar
  19. Lefebvre M, Marchand M, Horowitz JM, Torres G (1999) Detection of fluoxetine in brain, blood, liver and hair of rats using gas chromatography-mass spectrometry. Life Sci 64:805–811PubMedCrossRefGoogle Scholar
  20. Li L, Wen XZ, Bu ZD, Cheng XJ, Xing XF, Wang XH, Zhang LH, Guo T, Du H, Hu Y, Fan B, Ji JF (2016) Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells. Oncol Rep 35:3009–3017PubMedCrossRefGoogle Scholar
  21. Li P, Zhou L, Zhao T, Liu X, Zhang P, Liu Y, Zheng X, Li Q (2017a) Caspase-9: structure, mechanisms and clinical application. Oncotarget 8:23996–24008PubMedPubMedCentralGoogle Scholar
  22. Li Y, Zhou M, Hu Q, Bai XC, Huang W, Scheres SH, Shi Y (2017b) Mechanistic insights into caspase-9 activation by the structure of the apoptosome holoenzyme. Proc Natl Acad Sci U S A 114:1542–1547PubMedPubMedCentralCrossRefGoogle Scholar
  23. Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S (1993) Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 79:401–404PubMedCrossRefGoogle Scholar
  24. Liu KH, Yang ST, Lin YK, Lin JW, Lee YH, Wang JY, Hu CJ, Lin EY, Chen SM, Then CK, Shen SC (2015) Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis. Oncotarget 6:5088–5101PubMedGoogle Scholar
  25. Lu TH, Tseng TJ, Su CC, Tang FC, Yen CC, Liu YY, Yang CY, Wu CC, Chen KL, Hung DZ, Chen YW (2014) Arsenic induces reactive oxygen species-caused neuronal cell apoptosis through JNK/ERK-mediated mitochondria-dependent and GRP 78/CHOP-regulated pathways. Toxicol Lett 224:130–140PubMedCrossRefGoogle Scholar
  26. Ma J, Yang YR, Chen W, Chen MH, Wang H, Wang XD, Sun LL, Wang FZ, Wang DC (2016) Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. Oncol Rep 36:676–684PubMedPubMedCentralCrossRefGoogle Scholar
  27. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JP, Melendez-Zajgla J (2008) Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res 27:48PubMedPubMedCentralCrossRefGoogle Scholar
  28. McIlwain DR, Berger T, Mak TW (2015) Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 7PubMedPubMedCentralCrossRefGoogle Scholar
  29. Ming J, Ruan S, Wang M, Ye D, Fan N, Meng Q, Tian B, Huang T (2015) A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1. Oncotarget 6:40692–40703PubMedPubMedCentralCrossRefGoogle Scholar
  30. Mukherjee J, Das MK, Yang ZY, Lew R (1998) Evaluation of the binding of the radiolabeled antidepressant drug, 18F-fluoxetine in the rodent brain: an in vitro and in vivo study. Nucl Med Biol 25:605–610PubMedCrossRefGoogle Scholar
  31. Mun AR, Lee SJ, Kim GB, Kang HS, Kim JS, Kim SJ (2013) Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res 33:3691–3697PubMedGoogle Scholar
  32. Salakou S, Kardamakis D, Tsamandas AC, Zolota V, Apostolakis E, Tzelepi V, Papathanasopoulos P, Bonikos DS, Papapetropoulos T, Petsas T, Dougenis D (2007) Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo 21:123–132PubMedGoogle Scholar
  33. Salem Sokar S, Elsayed Elsayad M, Sabri Ali H (2016) Serotonin and histamine mediate gastroprotective effect of fluoxetine against experimentally-induced ulcers in rats. J Immunotoxicol 13:638–651PubMedCrossRefGoogle Scholar
  34. Sano R, Reed JC (2013) ER stress-induced cell death mechanisms. Biochim Biophys Acta 1833:3460–3470PubMedCrossRefGoogle Scholar
  35. Santarsieri D, Schwartz TL (2015) Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context 4:212290PubMedPubMedCentralCrossRefGoogle Scholar
  36. Sarrouilhe D, Mesnil M (2018) Serotonin and human cancer: a critical view. BiochimieGoogle Scholar
  37. Seger R, Krebs EG (1995) The MAPK signaling cascade. FASEB J 9:726–735PubMedCrossRefGoogle Scholar
  38. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, Bunce CM, Gregory CD, Barnes NM, Gordon J (2003) Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101:3212–3219PubMedCrossRefGoogle Scholar
  39. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Lee JK, Pisani P, Park JG (2005) Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer research and treatment : official journal of Korean Cancer Association 37:325–331CrossRefGoogle Scholar
  40. Stepulak A, Rzeski W, Sifringer M, Brocke K, Gratopp A, Kupisz K, Turski L, Ikonomidou C (2008) Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther 7:1685–1693PubMedCrossRefGoogle Scholar
  41. Sun D, Zhu L, Zhao Y, Jiang Y, Chen L, Yu Y, Ouyang L (2018) Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer. Cell Prolif 51:e12402PubMedCrossRefGoogle Scholar
  42. Tibbles LA, Woodgett JR (1999) The stress-activated protein kinase pathways. Cell Mol Life Sci 55:1230–1254PubMedCrossRefGoogle Scholar
  43. Wada T, Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838–2849PubMedCrossRefGoogle Scholar
  44. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A (2007) Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13:1070–1077PubMedCrossRefGoogle Scholar
  45. Wang WA, Groenendyk J, Michalak M (2014) Endoplasmic reticulum stress associated responses in cancer. Biochim Biophys Acta 1843:2143–2149PubMedCrossRefGoogle Scholar
  46. Waskiewicz AJ, Cooper JA (1995) Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol 7:798–805PubMedCrossRefGoogle Scholar
  47. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2009) Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf 18:284–290PubMedPubMedCentralCrossRefGoogle Scholar
  48. Yamaguchi H, Wang HG (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279:45495–45502PubMedCrossRefGoogle Scholar
  49. Zhai FG, Zhang XH, Wang HL (2009) Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin Exp Pharmacol Physiol 36:850–856PubMedCrossRefGoogle Scholar
  50. Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, Takano Y (2008) Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol 39:1042–1049PubMedCrossRefGoogle Scholar
  51. Zou H, Yang R, Hao J, Wang J, Sun C, Fesik SW, Wu JC, Tomaselli KJ, Armstrong RC (2003) Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J Biol Chem 278:8091–8098PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Laboratory of Signaling and Pharmacological Activity, Department of Pharmacology, College of PharmacyChung-Ang UniversitySeoulRepublic of Korea

Personalised recommendations